Back to today’s briefing

Story perspectives

Revolutionary Universal Vaccine Platform Set for 2026 Trials

5/2/2025

39 7

Summary

Story summary

On May 1, the U.S. Department of Health and Human Services and the National Institutes of Health unveiled the Generation Gold Standard, a groundbreaking universal vaccine platform. Utilizing a beta-propiolactone inactivated whole-virus method, this initiative targets influenza and coronaviruses, with clinical trials set to kick off in 2026 and FDA approval anticipated by 2029.

1 of 1

Story summary

On May 1, the U.S. Department of Health and Human Services and the National Institutes of Health unveiled the Generation Gold Standard, a groundbreaking universal vaccine platform. Utilizing a beta-propiolactone inactivated whole-virus method, this initiative targets influenza and coronaviruses, with clinical trials set to kick off in 2026 and FDA approval anticipated by 2029.